

Clinical Research

Ketamine for Depression

[“Sleep Drives Metabolite Clearance from the Adult Brain”](#) by Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, Department of Neuroscience and Physiology, Langone Medical Center, October 18, 2013

[“Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.”](#) by Am J Psychiatry, October 7, 2013

[“Ketamine as a Novel Antidepressant: From Synapse to Behavior”](#) by PubMed, June 5, 2013

[“Serial infusions of low-dose ketamine for major depression.”](#) by PubMed, February 20, 2013

[“Neurobiological advances identify novel antidepressant targets”](#) by PubMed, October 12, 2013

[“The Role of AMPA Receptor Modulation in the Treatment of Neuropsychiatric Diseases”](#) by May 1, 2009

[“Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression”](#) by PubMed, August 15, 2013

[“Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder”](#) by JAMA Psychiatry, June 2014

[“A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists”](#) by The Royal Society Publishing, July 23, 2012

[“NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses”](#) by Nature International Weekly Journal of Science

[“Signaling Pathways Underlying the Rapid Antidepressant Actions of Ketamine”](#) by US National Library of Medicine National Institutes of Health, January 1, 2013

[“Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression”](#) by James W. Murrough, Andrew M. Perez, Sarah Pillemer, Jessica Stern, Michael K. Parides, Marije aan het Rot, Katherine A. Collins, Sanjay J. Mathew, Dennis S. Charney, and Dan V. Iosifescu, 2012

[“Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression”](#) by Marije aan het Rot, Katherine A. Collins, James W. Murrough, Andrew M. Perez, David L. Reich, Dennis S. Charney, and Sanjay J. Mathew

[“Glutamate NMDA receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure”](#) by Nanxin Li, Rong-Jian Liu, Jason M. Dwyer,

Mounira Banasr, Boyoung Lee, Hyeon Son, Xiao-Yuan Li, George Aghajanian, and Ronald S. Duman, April 15, 2011

[“A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression”](#) by Nancy Diazgranados, MD, MS, Lobna Ibrahim, MD, Nancy E. Brutsche, MSN, Andrew Newberg, MD, Phillip Kronstein, MD, Sami Khalife, MD, William A. Kammerer, MD, Zenaide Quezado, MD, David A. Luckenbaugh, MA, Giacomo Salvatore, MD, Rodrigo MachadoVieira, MD, PhD, Hussein K. Manji, MD, FRCPC, and Carlos A. Zarate Jr, MD, August 2010

[“Maintenance Ketamine Treatment Produces Long-term Recovery from Depression”](#) by Michael M. Messer, MD, and Irina V. Haller, PhD, MS, 2010

[“NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses”](#) by Anita E. Autry , Megumi Adachi , Elena Nosyreva , Elisa S. Na , Maarten F. Los , Peng-fei Cheng , Ege T. Kavalali & Lisa M. Monteggia.

[“Targeting the Glutamatergic System to Treat Major Depressive Disorder”](#) by Daniel C. Mathews, Ioline D. Henter, and Carlos A. Zarate, Jr, July 9, 2012

[“Rapid Agent Restores Pleasure-seeking Ahead of Other Antidepressant Action”](#) by National Institute of Mental Health, October 17, 2014

[Ketamine: 50 Years of Modulating the Mind](#) by Linda Li Fron Hum Neurosci 2016